Eighty-three members of the House of Representatives signed a letter urging CMS to rescind the interim final rule, which implements round one of competitive bidding, before its April 18 implementation date.
The Obama Administration’s answer – NO WAY. Now, the battle in part, shifts to assuring small suppliers are given every opportunity to bid, and to keeping diabetes supplies as in Round One -- out of DMEPOS competitive bidding.
Bill Popomaronis, R.Ph., NCPA vice president, home health and long term care pharmacy services, provides his thoughts and explanations on the latest DME information from CMS.
